Pancreatic Cancer: Adjuvant Therapy: Tumor Boards

Product ID : PCAT17
Price: $15.00
This is a digital product. You will receive a link to your product from customerservice@asco.org within 1 hour of purchase confirmation. Shipping charges do not apply.
E-mail to a friend

Purchase

Description

     This is a case-based activity that includes discussion of a 65-year-old male, with no chronic medical problems but had a 40-pack year history of cigarette smoking.  He presented with painless jaundice. In the past three months he has lost 20 pounds. His father, who was also a smoker, died from pancreatic cancer at the age of 73. 

 

At the end of this course, participants should understand:

  1. Describe the criteria for resectability for pancreatic adenocarcinoma
  2. Understand the evolution of adjuvant therapy clinical trials over the last three decades
  3. Acknowledge the different practice patterns regarding the utilization of adjuvant radiation therapy
  4. Review the data supporting the use of capecitabine and gemcitabine in the adjuvant treatment of ductal adenocarcinoma of the pancreas from the ESPAC-4 trial
  5. Collaborate across different specialties and with all members of the oncology care team to provide effective and patient-centered treatment and supportive care

IMPORTANT NOTE: This course expires on January 18, 2020. Participants must complete all necessary course components by this date.

 

Purchase the 2017 ASCO Tumor Boards Bundle to access to all 2017 ASCO Tumor Boards for added savings. Purchased separately, these items would be $180 altogether. When bundled, you save $55http://shop.asco.org/atbs17_2017-asco-tumor-boards/

Recommended Products